<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35286710</PMID><DateCompleted><Year>2022</Year><Month>05</Month><Day>27</Day></DateCompleted><DateRevised><Year>2022</Year><Month>05</Month><Day>27</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2299-5684</ISSN><JournalIssue CitedMedium="Internet"><Volume>74</Volume><Issue>3</Issue><PubDate><Year>2022</Year><Month>Jun</Month></PubDate></JournalIssue><Title>Pharmacological reports : PR</Title><ISOAbbreviation>Pharmacol Rep</ISOAbbreviation></Journal><ArticleTitle>Preclinical evaluation of a microtubule PET ligand [<sup>11</sup>C]MPC-6827 in tau and amyotrophic lateral sclerosis animal models.</ArticleTitle><Pagination><StartPage>539</StartPage><EndPage>544</EndPage><MedlinePgn>539-544</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s43440-022-00359-y</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Microtubules are abundant in brain and their malfunctioning occurs in the early-to-advanced stages of neurodegenerative disorders. At present, there is no in vivo test available for a definitive diagnosis of most of the neurodegenerative disorders. Herein, we present the microPET imaging of microtubules using our recently reported Positron Emission Tomography (PET) tracer, [<sup>11</sup>C]MPC-6827, in transgenic mice models of tau pathology (rTg4510) and amyotrophic lateral sclerosis pathology (SOD1*G93A) and compared to corresponding age-matched controls.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Automated synthesis of [<sup>11</sup>C]MPC-6827 was achieved in a GE-FX2MeI/FX2M radiochemistry module. In vivo PET imaging studies of [<sup>11</sup>C]MPC-6827 (3.7&#x2009;&#xb1;&#x2009;0.8&#xa0;MBq) were performed in rTg4510 and SOD1*G93A mice groups and their corresponding littermates (n&#x2009;=&#x2009;5 per group). Dynamic PET images were acquired using a microPET Inveon system (Siemens, Germany) at 55&#xa0;min for rTg4510 and 30&#xa0;min for SOD1*G93A and corresponding controls. PET images were reconstructed using the 3D-OSEM algorithm and analyzed using VivoQuant version 4 (Invicro, MA). Tracer uptake in ROIs that included whole brain was measured as %ID/g over time to generate standardized uptake values (SUV) and time-activity curves (TACs).</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">[<sup>11</sup>C]MPC-6827 exhibit a trend of lower tracer binding in mouse models of Alzheimer's disease (tau pathology, line rTg4510) and Amyotrophic Lateral Sclerosis (line SOD1*G93A) compared to wild-type littermates.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Our finding indicates a trend of loss of microtubule binding of [<sup>11</sup>C]MPC-6827 in the whole brain of AD and ALS transgenic mice models compared to control mice. The pilot studies described herein show that [<sup>11</sup>C]MPC-6827 could be used as a PET ligand for preclinical and human brain imaging of Alzheimer's disease, ALS, and other neurodegenerative diseases. Preclinical Evaluation of a Microtubule PET Ligand [<sup>11</sup>C]MPC-6827 in Tau and Amyotrophic Lateral Sclerosis Animal Models. J. S. Dileep Kumar, Andrei Molotkov, Jongho Kim, Patrick Carberry, Sidney Idumonyi, John Castrillon, Karen Duff, Neil A. Shneider, Akiva Mintz.</AbstractText><CopyrightInformation>&#xa9; 2022. The Author(s) under exclusive licence to Maj Institute of Pharmacology Polish Academy of Sciences.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kumar</LastName><ForeName>J S Dileep</ForeName><Initials>JSD</Initials><Identifier Source="ORCID">0000-0001-6688-3991</Identifier><AffiliationInfo><Affiliation>Division of Molecular Imaging and Neuropathology, New York State Psychiatric Institute, New York, USA. dkumar7@northwell.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Feinstein Institutes for Medical Research, North Shore University Hospital, Manhasset, New York, USA. dkumar7@northwell.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Molotkov</LastName><ForeName>Andrei</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Radiology, Columbia University Medical Center, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Jongho</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Radiology, Columbia University Medical Center, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Carberry</LastName><ForeName>Patrick</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Radiology, Columbia University Medical Center, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Idumonyi</LastName><ForeName>Sidney</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Radiology, Columbia University Medical Center, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Castrillon</LastName><ForeName>John</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Radiology, Columbia University Medical Center, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Duff</LastName><ForeName>Karen</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Pathology and Cell Biology and Taub Institute, Columbia University Medical Center, New York, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>UK Dementia Research Institute, University College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shneider</LastName><ForeName>Neil A</ForeName><Initials>NA</Initials><AffiliationInfo><Affiliation>Department of Neurology and Eleanor and Lou Gehrig ALS Center, Columbia University Medical Center, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mintz</LastName><ForeName>Akiva</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Division of Molecular Imaging and Neuropathology, New York State Psychiatric Institute, New York, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Radiology, Columbia University Medical Center, New York, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>UL1TR001873</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1TR001873</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>03</Month><Day>14</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Pharmacol Rep</MedlineTA><NlmUniqueID>101234999</NlmUniqueID><ISSNLinking>1734-1140</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008024">Ligands</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011799">Quinazolines</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.15.1.1</RegistryNumber><NameOfSubstance UI="D013482">Superoxide Dismutase</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.15.1.1</RegistryNumber><NameOfSubstance UI="D000072105">Superoxide Dismutase-1</NameOfSubstance></Chemical><Chemical><RegistryNumber>X97O9FTB92</RegistryNumber><NameOfSubstance UI="C522974">verubulin</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="Y">Alzheimer Disease</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008024" MajorTopicYN="N">Ligands</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008870" MajorTopicYN="N">Microtubules</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D049268" MajorTopicYN="N">Positron-Emission Tomography</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011799" MajorTopicYN="N">Quinazolines</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013482" MajorTopicYN="N">Superoxide Dismutase</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000072105" MajorTopicYN="N">Superoxide Dismutase-1</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Alzheimer&#x2019;s disease</Keyword><Keyword MajorTopicYN="N">Amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">Microtubule</Keyword><Keyword MajorTopicYN="N">PET</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>11</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>2</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>2</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>3</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>5</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>3</Month><Day>14</Day><Hour>17</Hour><Minute>21</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35286710</ArticleId><ArticleId IdType="doi">10.1007/s43440-022-00359-y</ArticleId><ArticleId IdType="pii">10.1007/s43440-022-00359-y</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Fan HC, Chi CS, Lee YJ, Tsai JD, Lin SZ, Harn HJ. The role of gene editing in neurodegenerative diseases. Cell Transplant. 2018;27(3):364&#x2013;78.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0963689717753378</ArticleId></ArticleIdList></Reference><Reference><Citation>Sheikh S, Safia HE, Mir SS. Neurodegenerative diseases: multifactorial conformational diseases and their therapeutic interventions. J Neurodegener Dis. 2013;2013:563481.</Citation><ArticleIdList><ArticleId IdType="pubmed">26316993</ArticleId></ArticleIdList></Reference><Reference><Citation>Nery TGM, Silva EM, Tavares R, Passetti F. The challenge to search for new nervous system disease biomarker candidates: the opportunity to use the proteogenomics approach. J Mol Neurosci. 2019;67(1):150&#x2013;64.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12031-018-1220-1</ArticleId></ArticleIdList></Reference><Reference><Citation>Varidaki A, Hong Y, Coffey ET. Repositioning microtubule stabilizing drugs for brain disorders. Front Cell Neurosci. 2018;12:226.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fncel.2018.00226</ArticleId></ArticleIdList></Reference><Reference><Citation>Brunden KR, Lee VM, Smith AB 3rd, Trojanowski JQ, Ballatore C. Altered microtubule dynamics in neurodegenerative disease: Therapeutic potential of microtubule-stabilizing drugs. Neurobiol Dis. 2017;105:328&#x2013;35.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2016.12.021</ArticleId></ArticleIdList></Reference><Reference><Citation>Matamoros AJ, Baas PW. Microtubules in health and degenerative disease of the nervous system. Brain Res Bull. 2016;126(Pt 3):217&#x2013;25.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.brainresbull.2016.06.016</ArticleId></ArticleIdList></Reference><Reference><Citation>Sleigh JN, Rossor AM, Fellows AD, Tosolini AP, Schiavo G. Axonal transport and neurological disease. Nat Rev Neurol. 2019;15:691&#x2013;703.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41582-019-0257-2</ArticleId></ArticleIdList></Reference><Reference><Citation>Salvadores N, Sanhueza M, Manque P, Court FA. Axonal degeneration during aging and its functional role in neurodegenerative disorders. Front Neurosci. 2017;11:451.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnins.2017.00451</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu X-A, Rizzo V, Puthanveettil SV. Pathologies of axonal transport in neurodegenerative diseases. Transl Neurosci. 2012;3(4):355&#x2013;72.</Citation><ArticleIdList><ArticleId IdType="doi">10.2478/s13380-012-0044-7</ArticleId></ArticleIdList></Reference><Reference><Citation>Oberstadt M, Cla&#xdf;en J, Arendt T, Holzer M. TDP-43 and cytoskeletal proteins in ALS. Mol Neurobiol. 2017;55(4):3143&#x2013;53.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12035-017-0543-1</ArticleId></ArticleIdList></Reference><Reference><Citation>Clark JA, Yeaman EJ, Blizzard CA, Chuckowree JA, Dickson TC. A case for microtubule vulnerability in amyotrophic lateral sclerosis: altered dynamics during disease. Front Cell Neurosci. 2016;10:204.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fncel.2016.00204</ArticleId></ArticleIdList></Reference><Reference><Citation>Fanara P, Banerjee J, Hueck RV, Harper MR, Awada M, Turner H, Husted KH, Brandt R, Hellerstein MK. Stabilization of hyperdynamic microtubules is neuroprotective in amyotrophic lateral sclerosis. J Biol Chem. 2007;282(32):23465&#x2013;72.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M703434200</ArticleId></ArticleIdList></Reference><Reference><Citation>Dubey J, Ratnakaran N, Koushika SP. Neurodegeneration and microtubule dynamics: death by a thousand cuts. Front Cell Neurosci. 2015;9:343.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fncel.2015.00343</ArticleId></ArticleIdList></Reference><Reference><Citation>Van der Veldt AAM, Lammertsma AA. In vivo imaging as a pharmacodynamic marker. Clin Cancer Res. 2014;20(10):2569&#x2013;77.</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/1078-0432.CCR-13-2666</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumar JSD, Solingapuram SKK, Prabhakaran J, Oufkir HR, Ramanathan G, Whitlow CT, et al. Radiosynthesis and in vivo evaluation of [11C]MPC-6827, the first brain penetrant microtubule PET ligand. J Med Chem. 2018;61(5):2118&#x2013;23.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.jmedchem.8b00028</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumar JSD, Prabhakaran J, Damuka N, Hines JW, Norman S, Meghana DM, et al. In vivo comparison of N-11CH3 vs O-11CH3 radiolabeled microtubule targeted PET ligands. Bioorg Med Chem Let. 2020;30(2):126785.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bmcl.2019.126785</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumar JSD, Molotkov A, Salling MC, Carberry P, Prabhakaran J, Castrillon J, Mintz A. In vivo evaluation of a microtubule PET ligand, [(<sup>11</sup>)C]MPC-6827, in mice following chronic alcohol consumption. Pharmacol Rep. 2022;74(1):241&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s43440-021-00311-6</ArticleId></ArticleIdList></Reference><Reference><Citation>https://www.alzforum.org/research-models/rtgtaup301l4510 ALZFORUM website accessed on October 4, 2021.</Citation></Reference><Reference><Citation>https://www.alzforum.org/research-models/sod1-g93a-hybrid-g1h ALZFORUM website accessed on October 4, 2021.</Citation></Reference><Reference><Citation>Checkoway H, Lundin JI, Kelada SN. Neurodegenerative diseases. IARC Sci Publ. 2011;163:407&#x2013;19.</Citation></Reference><Reference><Citation>Erkkinen MG, Kim MO, Geschwind MD. Clinical neurology and epidemiology of the major neurodegenerative diseases. Cold Spring Harb Perspect Biol. 2018;10(4):a033118.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/cshperspect.a033118</ArticleId></ArticleIdList></Reference><Reference><Citation>Heemels MT. Neurodegenerative diseases. Nature. 2016;539:179.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/539179a</ArticleId></ArticleIdList></Reference><Reference><Citation>Picher-Martel V, Valdmanis PN, Gould PV, Julien JP, Dupre N. From animal models to human disease: a genetic approach for personalized medicine in ALS. Acta Neuropathol Commun. 2016;4(1):70.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40478-016-0340-5</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>